An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

• Status: Terminated
• Trial end date: 2020-01-29
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Dasatinib; Ipilimumab; Linrodostat; Nivolumab

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Advanced Non Small Cell Lung Cancer (NSCLC)

• Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 1

• Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy treatment

• Must have at least 1 lesion with measurable disease

Exclusion Criteria:

• Subjects with certain mutations that have not been treated with a targeted therapy prior to enrollment

• Subjects who need daily oxygen therapy

• People with autoimmune disease

Other protocol defined inclusion/exclusion criteria could apply